10X Genomics, Inc. SEC Filings

Serge Saxonov, who serves as Chief Executive Officer and a director of 10x Genomics, Inc. (TXG), reported a transaction on 08/22/2025 in which 9,348 shares of Class A common stock were sold at a price of $13.787 per share. The filing indicates the sale was made to cover tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the filing shows 945,892 shares held directly and additional indirect holdings reported as: 27, 89,825, 213,250, and 58,000 shares, each held via trusts for which the reporting person serves as trustee. The Form 4 was signed by an attorney-in-fact on 08/26/2025.

10x Genomics insider sale by CFO Adam Taich, the company's Chief Financial Officer and reporting person, reported a sale of 22,315 shares of Class A Common Stock on 08/22/2025 at a price of $13.787 per share. Following the sale, Mr. Taich beneficially owned 309,273 shares, reported as direct ownership. The filing explains the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Taich on 08/26/2025.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (Ticker: TXG), reported a sale of 7,486 shares of Class A common stock on 08/22/2025 at a price of $13.787 per share. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. After the transaction, Mr. Hindson beneficially owned 440,888 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Hindson on 08/26/2025. The filing lists Mr. Hindson as both a director and an officer of the issuer.

10x Genomics (TXG) Form 144 notice: The filing reports a proposed sale of 9,228 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $123,747.48, and an approximate sale date of 08/22/2025 on NASDAQ. The securities were acquired as a Restricted Stock Unit grant on 08/21/2025 totaling 25,785 shares, with payment characterized as services rendered. The filer discloses one prior sale in the last three months: Serge Saxonov sold 9,343 shares on 05/22/2025 for $77,540.36. The notice includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.

10x Genomics (TXG) filed a Form 144 reporting a proposed sale under Rule 144 of 7,393 shares of common stock with an aggregate market value of $99,140.13, planned on 08/22/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

The shares were acquired as a Restricted Stock Unit grant from the issuer on 08/21/2025 totaling 20,657 units and paid as services rendered. The filer also sold 7,485 shares on 05/22/2025 for gross proceeds of $62,120.26. The notice includes the standard representation that the selling person is not aware of undisclosed material adverse information.

10x Genomics (TXG) Form 144 notice shows a proposed sale of 22,037 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $295,516.17 and an approximate sale date of 08/22/2025 on NASDAQ. The filing reports the shares were acquired as a Restricted Stock Unit grant on 08/21/2025 with 61,587 units noted as acquired and payment described as Services Rendered. It also discloses a prior sale by the same person of 4,044 shares on 05/22/2025 for gross proceeds of $33,562.37. The filer affirms no undisclosed material adverse information.

Nikko Asset Management Americas, Inc. filed a Schedule 13G reporting beneficial ownership of 6,009,653 shares of 10x Genomics, Inc. Class A common stock, representing 5.4% of the class. The filing discloses shared voting power for 5,605,769 shares and shared dispositive power for 6,009,653 shares, with no sole voting or dispositive power reported.

The statement includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing identifies the filer and issuer addresses and is signed by Gary L. Beckham, Chief Compliance Officer.

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported beneficial ownership of 3,060,859 shares of 10x Genomics, Inc. Class A common stock, representing 2.7% of the class. The cover pages show shared voting power of 2,979,280 shares and shared dispositive power of 3,060,859, with no sole voting or dispositive power reported by the filing parties.

The statement is submitted on a Schedule 13G/A and includes a joint filing agreement among the reporting persons. The filing also states that the shares are held by entities subject to voting control and investment discretion by Millennium Management and related managers, and disclaims that this alone constitutes admission of beneficial ownership.